SEARCH

SEARCH BY CITATION

References

  • Akishita M., Hashimoto M., Ohike Y., Ogawa S., Iijima K., Eto M., Ouchi Y.. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res. 2007;30: 10291034.
  • Allan CA, Strauss BJG, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in non-obese aging men. J Clin Endocrinol Metab. 2008;93: 139146.
  • Allan CA, Strauss BJ, McLachlan RI. Body composition, metabolic syndrome and testosterone in ageing men [review]. Int J Impo Res. 2007;19: 448457.
  • Bansal TC, Guay AT, Jacobson J., Woods BO, Nesto RW. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med. 2005;2: 96103.
  • Basu R., Man CD, Campioni M., Basu A., Nair KS, Jensen MD, Khosla S., Klef G., Toffolo G., Cobelli C., Rizza RA. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care. 2007;30: 19721978.
  • Bataille V., Perret B., Dallongeville J., Arveiler D., Yarnell J., Ducimetiere P., Ferrieres J.. Metabolic syndrome and coronary heart disease risk in a population-based study of middle-aged men from France and Northern Ireland. Diabetes Metab. 2006;32: 475479.
  • Blouin K., Despres JP, Couillard C., Tremblay A., Prud'homme D., Bouchard C., Tchernof A.. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism. 2005;54: 10341040.
  • Blouin K., Richard C., Brochu G., Hould FS, Lebel S., Marceau S., Biron S., Luu-The V., Tchernof A.. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. J Endocrinol. 2006;191: 637649.
  • Bocchio M., Desideri G., Scarpelli P., Necozione S., Properzi S., Spartera C., Francavilla F., Ferri C., Francavilla S.. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factor and overt vascular damage. J Urol. 2004;171: 16011604.
  • Bojesen A., Kristensen K., Birkebaek NH, Fedder J., Mosekilde L., Bennett P., Laurberg P., Frystyk J., Flyvbjerg A., Christiansen JS, Gravholt CH. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care. 2006;29: 15911598.
  • Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Meigs JB, Bonadonna RC, Muggeo M.. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population. Diabetes Care. 2007;30: 318324.
  • Boyanov MA, Boneva Z., Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6: 17.
  • Braga-Basaria M., Dobs AS, Muller DC, Carducci MA, John M., Egan J., Basarla S.. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24: 39793983.
  • Calles-Escandon J., Cipolla M.. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001;22: 3652.
  • Calles-Escandon J., Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes. 1998;47: 290293.
  • Chen RY, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes Obes Metab. 2006;8: 429435.
  • Chen Z., Maricic M., Nguyen P., Ahmann FR, Bruhn R., Dalkin BL. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 2002;95: 21362144.
  • Corona G., Mannucci E., Petrone L., Balercia G., Paggi F., Fisher AD, Lotti F., Chiarini V., Fedele D., Forti G., Maggi M.. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med. 2007b;4: 10381045.
  • Corona G., Mannucci E., Petrone L., Ricca V., Balercia G., Mansani R., Chiarini V., Giommi R., Forti G., Maggi M.. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res. 2006a;18: 190197.
  • Corona G., Mannucci E., Petrone L., Schulman C., Balercia G., Fisher AD, Chiarini V., Forti G., Maggi M.. A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med. 2007a;4: 789796.
  • Corona G., Mannucci E., Schulman C., Petrone L., Mansani R., Cilotti A., Balercia G., Chiarini V., Forti G., Maggi M.. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol. 2006b;50: 595604.
  • D'Amico AV, Denham JW, Crook J., Chen MH, Goldhaber SZ, Lamb DS, Joseph D., Tai KH, Malone S., Ludgate C., Steigler A., Kantoff PW. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction. J Clin Oncol. 2007;25: 24202425.
  • Demir T., Demir O., Kefi A., Comlekci A., Yesil S., Esen A.. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int J Urol. 2006;13: 385388.
  • Esposito K., Ciotola M., Giugliano F., DeSio M., Giugliano G., D'armiento M., Giugliano D.. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res. 2006;18: 405410.
  • Esposito K., Ciotola M., Marfella R., Di Tommaso D., Cobellis L., Giugliano D.. Sexual dysfunction in women with the metabolic syndrome. Diabetes Care. 2005;28: 756.
  • Esposito K., Giugliano F., Martedi E., Feola G., Marfella R., D'Armiento M., Giugliano D.. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care. 2004;28: 12011203.
  • European Group for the Study of Insulin Resistance (EGIR) Frequency of the WHO metabolic syndrome in European cohorts and an alternative definition of an insulin resistance syndrome. Diabetes Metab (Paris). 2002;28: 364376.
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: 24862497.
  • Ferrannini E., Balkau B., Coppack SW, Dekker JM, Mari A., Nolan J., Walker M., Natali A., Beck-Nielsen and the RISC Investigators Insulin resistance insulin response and obesity as indicators of metabolic risk. J Clin Endocrinol Metab. 2007;92: 28852892.
  • Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287: 356359.
  • Ford ES, Li C.. Physical activity or fitness and the metabolic syndrome. Expert Rev Cardiovasc Ther. 2006;4: 897915.
  • Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106: 453458.
  • Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Eastell R., Davies HA, Snowden JA, Derogatis L., Shalet SM, Ross RJM. Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study. J Clin Endocrinol Metab. 2007;92: 34763484.
  • Guay AT. Relation of endothelial cell function to erectile dysfunction: implications for treatment. Am J Cardiol. 2005;96: 52M56M.
  • Guay AT. ED2: erectile dysfunction equals endothelial dysfunction. Endocrinol Metab Clin N Am. 2007;36: 453463.
  • Guay A., Jacobson J.. The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med. 2007;4: 10461055.
  • Guize L., Thomas F., Pannier B., Bean K., Jego B., Benetos A.. All-cause mortality associated with specific combinations of the metabolic syndrome according to recent definitions. Diabetes Care. 2007;30: 23812387.
  • Gustafson B., Hammarstedt A., Andersson CX, Smith U.. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27: 22762283.
  • Gutierrez-Fisac JL, Lopez E., Banegas J.R., Graciani A., Rodriguez-Artalejo F.. Prevalence of overweight and obesity in elderly people in Spain. Obes Res. 2004;12: 710715.
  • Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K., Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82: 2939.
  • Haider A., Yassin A., Saad F., Shabsigh R.. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male. 2007;10: 189196.
  • Hanefeld M., Leonhardt W.. Das metabolische Syndrom. Dtsch Gesundheitwes. 1981;36: 545551.
  • He Y., Jiang B., Wang J., Feng K., Chang Q., Zhu S., Fan L., Li X., Hu FB. BMI versus the metabolic syndrome in relation to cardiovascular risk in elderly Chinese individuals. Diabetes Care. 2007;30: 21282134.
  • Heidler S., Temml C., Broessner C., Mock K., Rauchenwald M., Madersbacher S., Ponholzer A.. Is the metabolic syndrome an independent risk factor for erectile dysfunction? J Urol. 2007;177: 651654.
  • Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch-Johnsen K., Pyorala K., Study DECODE Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164: 10661076.
  • Imam SK, Shahid SK, Hassan A., Alvi Z.. Frequency of the metabolic syndrome in type 2 diabetic subjects attending the diabetes clinic of a tertiary care hospital. J Pak Med Assoc. 2007;57: 239242.
  • Ingelsson E., Arnlov J., Lind L., Sundstrom J.. Metabolic syndrome and risk for heart failure in middle-aged men. Heart. 2006;92: 14091413.
  • International Diabetes Federation. The IDF Consensus worldwide definition of the metabolic syndrome. www.idf.orgwebdataMetac_syndrome_def.pdf. Accessed August 1, 2007.
  • Ishikawa T., Fujioka H., Ishimura T., Takenaka A., Fujisawa M.. Ghrelin expression in human testis and serum testosterone level. J Androl. 2007;28: 320324.
  • Isidori AM, Caprio M., Strollo F., Moretti C., Frajese G., Isidori A., Fabbri A.. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999;84: 36733680.
  • Isidori AM, Giannetta E., Greco EA, Gianfrilli D., Bonifacio V., Isidori A., Lenzi A., Fabbri A.. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol. 2005;63: 280293.
  • Isidori AM, Strollo F., More M., Caprio M., Aversa A., Moretti C., Frajese G., Riondino G., Fabbri A.. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metab. 2000;85: 19541962.
  • Kaplan SA, Meehan AG, Shah A.. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol. 2006;176: 15241528.
  • Kapoor D., Goodwin E., Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154: 899906.
  • Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes. 2007;14: 226234.
  • Katznelson L., Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A.. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81: 43584365.
  • Kupelian V., Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006a;91: 843850.
  • Kupelian V., Shabsigh R., Araujo AB, O'Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol. 2006b;176: 222226.
  • Laaksonen DE, Niskanen L., Punnonen K., Nyyssonen K., Tuomainen TP, Salonen R., Rauramaa R., Salonen JT. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol. 2003;149: 601608.
  • Laaksonen DE, Niskanen L., Punnonen K., Nyyssonen K., Tuomainen TP, Valkonen VP, Salonen JT. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2005;90: 712719.
  • Lage MJ, Barber BL, Markus RA. Association of androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology. 2007;70: 11041108.
  • Lee SJ, Gungor N., Bacha F., Arslanian S.. Insulin resistance: link to the components of the metabolic syndrome and biomarkers of endothelial dysfunction in youth. Diabetes Care. 2007;30: 20912097.
  • Lee WY, Park JS, Noh SY, Rhee EJ, Kim SW, Zimmet PZ. Prevalence of the metabolic syndrome among 40,698 Korean metropolitan subjects. Diab Res Clin Pract. 2004;65: 143149.
  • Lorenzo C., Serrano-Rios M., Martinez-Larrad MT, Gonzalez-Villapando C., Gonzalez-Sanchez JL, Martinez-Calatrava MJ, Gabriel R., Haffner SM. Is waist circumference an essential component of the metabolic syndrome? Diabetes Care. 2007a;30: 21412142.
  • Lorenzo C., Williams K., Hunt KJ, Haffner SM. The National Cholesterol Education program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007b;30: 813.
  • Makhsida N., Shah J., Yan G., Fisch H., Shabsigh R.. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005;174: 827834.
  • Marin P., Holmang S., Gustafsson C., Jonsson L., Kvist H., Elander A., Eldh J., Sjostrom L., Holm G., Bjorntorp P.. Androgen treatment of abdominally obese men. Obes Res. 1993;1: 245251.
  • Marin P., Holmang S., Jonsson L., Sjostrom L., Kvist H., Holm G., Lindstedt G., Bjorntorp P.. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992;16: 991997.
  • McVeigh GE, Cohn JN. Endothelial dysfunction and the metabolic syndrome. Curr Diab Rep. 2003;3: 8792.
  • Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB, Wilson PWF. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30: 12191225.
  • Miner MM, Sadovsky R.. Evolving issues in male hypogonadism: evaluation, management, and related comorbidities. Clevel Clin J Med. 2007;74: S38S46.
  • Miner MM, Seftel AD. Testosterone and aging: what we have learned since the Institute of Medicine and what lies ahead. Int J Clin Prac. 2007;61: 622632.
  • Muller M., Grobbee DE, den Tonkelaar I., Lamberts SW, van Der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90: 26182623.
  • Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am. 2003;32: 741760.
  • Oh JY, Hong YS, Sung YA, Barrett-Connor E.. Prevalence and factor analysis of metabolic syndrome in an urban Korean population. Diabetes Care. 2004;27: 20272032.
  • Osuna JA, Gomez-Perez R., Arata-Bellabarba G., Villaroel V.. Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men. Arch Androl. 2006;52: 355361.
  • Padmanahbhan P., McCullough AR. Penile oxygen saturation in the flaccid and erect penis in men with and without erectile dysfunction. J Androl. 2007;28: 223228.
  • Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90: 15021510.
  • Pagotto U., Gambineri A., Pelusi C., Genghini S., Cacciari M., Otto B., Castaneda T., Tschop M., Pasquali R.. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab. 2003;88: 41394143.
  • Paick JS, Yang JH, Kim SW, Ku JH. Severity of erectile dysfunction in married impotent patients: interrelationship with anthropometry, hormones, metabolic profiles and lifestyle. Int J Urol. 2007a;14: 4853.
  • Paick JS, Yang JH, Kim SW, Ku JH. Are age, anthropometry and components of metabolic syndrome-risk factors interrelated with lower urinary tract symptoms in patients with erectile dysfunction? A prospective study. Asian J Androl. 2007b;9: 213220.
  • Park YW, Zhu S., Palaniappan L., Heshka S., Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003;163: 427436.
  • Pasquali R., Casimirri F., Cantobelli S., Melchionda N., Labate Morselli AM, Fabbri R., Capelli M., Bortoluzzi L.. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism. 1991;40: 101104.
  • Pasquali R., Macor C., Vicennati V., Novo F., de Lasio R., Mesini P., Boschi S., Casimirri F., Vettor R.. Effects of acute hyperinsulinemia on testosterone serum concentrations in adult obese and normal-weight men. Metabolism. 1997;46: 526529.
  • Reaven GM, Lithell H., Landsberg L.. Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334: 374381.
  • Riedner CE, Rhoden EL, Ribeiro EP, Fuchs SC. Central obesity is an independent predictor of erectile dysfunction in older men. J Urol. 2006;176: 15191523.
  • Rodriguez A., Muller DC, Metter EJ, Maggio M., Harman SM, Blackman MR, Andres R.. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab. 2007;92: 35685372.
  • Rogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M., Knekt P., van Dam RM, Hu FB, BMI-CHD Collaboration Investigators, Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21cohort studies including more than 300,000 persons. Arch Intern Med. 2007;167: 17201728.
  • Rosano GMC, Sheiban I., Massaro R., Pagnotta P., Marazzi G., Vitale C., Mercuro G., Volterrani M., Aversa A., Fini M.. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res. 2007;19: 176182.
  • Rosmond R., Wallerius S., Wanger P., Martin L., Holm G., Bjorntorp P.. A 5 year follow-up study of disease incidence in men with an abnormal hormone pattern. J Intern Med. 2003;254: 386390.
  • Saad F., Gooren L., Haider A., Yassin A.. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. Andrologia. 2008a;40: 4448.
  • Saad F., Gooren LJ, Haider A., Yassin A.. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl. 2008b;29: 102105.
  • Seidell JC, Bjorntorp P., Sjostrom L., Kvist H., Sannerstedt R.. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990;39: 897901.
  • Selvin E., Feinleib M., Zhang L., Rohrmann S., Rifai N., Nelson W., Dobs A., Basaria S., Golden S., Platz E.. Androgens and diabetes in men. Diabetes Care. 2007;30: 234238.
  • Shabsigh R., Arver S., Channer KS, Eardley I., Fabbri A., Gooren L., Heufelder A., Jones H., Meryn S., Zitzman M.. The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract. 2008;62: 791798.
  • Shabsigh R., Perelman MA, Lockhart DC, Lue TF, Broderick GA. Health issues of men: prevalence and correlates of erectile dysfunction. J Urol. 2005;174: 662667.
  • Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87: 599603.
  • Smith MR, Lee H., Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91: 13051308.
  • Sobel BE. Insulin resistance and thrombosis: a cardiologist's view. Am J Cardiol. 1999;84: 37J41J.
  • Stoch SA, Parker RA, Chen L., Bubley G., Ko YJ, Vincelette A., Greenspan SL. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86: 27872791.
  • Svartberg J.. Epidemiology: testosterone and the metabolic syndrome. Int J Impot Res. 2007;19: 124128.
  • Svartberg J., vo Muhlen D., Schirmer H., Barrett-Connor E., Sundfjord J., Jorde R.. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol. 2004a;150: 6571.
  • Svartberg J., vo Muhlen D., Sundsfjord J., Jorde R.. Waist circumference and testosterone levels in community dwelling men. The Tromso Study. Eur J Epidemiol. 2004b;19: 657663.
  • Swerdloff RS, Wang C.. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male. 2003;6: 207211.
  • Tan KC, Shiu SW, Pang RW, Kung AW. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin Endocrinol (Oxf). 1998;48: 187194.
  • Tanomsup S., Aekplakorn W., Sritara P., Woodward M., Yamwong S., Tunlayadechanont S., Tatsaneeyapan A., Lim S., Rajatanavin R.. A comparison of components of two definitions of the metabolic syndrome related to cardiovascular disease and all-cause mortality in a cohort study in Thailand. Diabetes Care. 2007;30: 21382140.
  • Taskinen MR. Is metabolic syndrome the main threat to human health in the twenty-first century? Arterioscler Thromb Vasc Biol. 2007;27: 2275.
  • Tena-Sempere M., Barreiro ML, Gonzalez LC, Gaytan F., Zhang FP, Caminos JE, Pinilla L., Casanueva FF, Dieguez C., Aguilar E.. Novel expression and functional role of ghrelin in rat testis. Endocrinology. 2002;143: 717725.
  • Tena-Sempere M., Pinilla L., Gonzalez LC, Dieguez C., Casanueva FF, Aguilar E.. Leptin inhibits testosterone secretion from adult rat testis in vitro. J Endocrinol. 1999;161: 211218.
  • Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75: 10921098.
  • Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2007;294: 29963002.
  • Torigoe M., Matsui H., Ogawa Y., Murakami H., Murakami R., Cheng XW, Numaguchi Y., Murohara T., Okumura K.. Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men. Clin Endocrinol. 2007;67: 276281.
  • vo Hafe P., Pina F., Perez A., Tavares M., Barros H.. Visceral fat accumulation as a risk factor for prostate cancer. Obes Res. 2004;12: 19301935.
  • Wang C., Cunningham G., Dobs A., Iranmanesh A., Matsumoto AM, Snyder PJ, Weber T., Berman N., Hull L., Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89: 20852098.
  • Wang C., Swerdloff RS. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab. 2002;87: 14621466.
  • Wang C., Swerdloff RS, Iranmanesh A., Dobs A., Snyder PJ, Cunningham G., Matsumoto AM, Wang J., Ruotsalainen S., Moilanen L., Lepisto P., Laakso M., Kuusisto J.. Metabolic syndrome and incident end-stage peripheral vascular disease. Diabetes Care. 2007;30: 30993104.
  • Wang C., Swerdloff RS, Iranmanesh A., Dobs A., Snyder PJ, Cunningham G., Matsumoto AM, Weber T., Berman N.; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85: 28392853.
  • Wannamethee SG, Shaper AG, Morris RW, Whincup PH. Measures of adiposity in the identification of metabolic abnormalities in elderly men. Am J Clin Nutr. 2005;81: 13131321.
  • Yannucci J., Manola J., Garnick MB, Bhat G., Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006;176: 520525.
  • Yialamas MA, Dwyer AA, Hanley E., Pitteloud N LeeHang, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2007;92: 42544259.
  • Zgliczynski S., Ossowski M., Slowinska-Srzednicka J., Brzezinska A., Zgliczynski W., Soszynski P., Chotkowska E., Srzednicki M., Sadowski Z.. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis. 1996;121: 3543.
  • Zhody W., Kamal EE, Ibrahim Y.. Androgen deficiency and abnormal penile duplex parameters in obese men with erectile dysfunction. J Sex Med. 2007;4: 797808.